-

Fluor Completes Bayer’s First Global Cell Therapy Launch Facility in Berkeley, California

Second new facility built by Fluor on Bayer’s Biotech campus in Berkeley

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced today that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees and clients.

Fluor completes Bayer’s first global Cell Therapy Launch Facility in Berkeley, California

Share

“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”

The new state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs.

Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 40,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $13.7 billion in 2022 and is ranked 303 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#ATLS

Contacts

Brett Turner
Media Relations
864.281.6976

Jason Landkamer
Investor Relations
469.398.7222

Fluor Corporation

NYSE:FLR

Release Summary
Fluor Completes Bayer’s First Global Cell Therapy Launch Facility in Berkeley, California
Release Versions

Contacts

Brett Turner
Media Relations
864.281.6976

Jason Landkamer
Investor Relations
469.398.7222

Social Media Profiles
More News From Fluor Corporation

Fluor Announces Appointment of Robert G. (Bob) Card to its Board of Directors

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced today that Robert G. (Bob) Card, former President and CEO of SNC‑Lavalin and a seasoned global engineering and construction executive, has been elected to its Board of Directors effective March 4, 2026. Card will serve on the Board’s Audit Committee and Commercial Strategies and Operational Risk Committee. Card’s appointment brings the total number of Fluor Board members to 12 of whom 10 are independent. With more than thre...

Fluor Announces Retirement of Executive Chairman, David E. Constable, and Appointment of James T. (Jim) Hackett as Chairman of the Board

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) today announced that David E. Constable, Executive Chairman, will step down from the Board of Directors following the Annual Shareholders Meeting on May 6, 2026. James T. (Jim) Hackett, the company’s Lead Independent Director, will assume the role of Chairman of the Board on May 5, 2026. Constable’s connection to Fluor spans 44 years. He began his career with the company in 1982, advancing through a series of global leadership roles...

Fluor Receives $1.35 Billion for 71 Million NuScale Shares; Launches Trading Program for Remaining 40 Million Shares

IRVING, Texas--(BUSINESS WIRE)--FLUOR RECEIVES $1.35 BILLION FOR 71 MILLION NUSCALE SHARES; LAUNCHES TRADING PROGRAM FOR REMAINING 40 MILLION SHARES...
Back to Newsroom